2024
DOI: 10.1055/s-0044-1779737
|View full text |Cite
|
Sign up to set email alerts
|

Innovative Therapies for Acquired Hemophilia A

Massimo Franchini,
Daniele Focosi

Abstract: Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder which can be life-threatening. AHA is due to autoantibodies against coagulation factor VIII. Disease onset may be idiopathic (approximately half of the cases) or triggered by autoimmune disorders, cancers, drugs, infections, or pregnancy. Besides treating the underlying disorder, specific AHA treatments include management of bleeding and inhibitor eradication. Various first-line and second-line hemostatic and immunosuppressive agents are curren… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 32 publications
0
2
0
Order By: Relevance
“…When rpFVIII is chosen as the initial treatment, a dose of 200 U/kg, followed by additional doses to sustain the levels of FVIII > 50% through the treatment, is used [87]. Studies are suggesting that, during therapy with rpFVIII, the activity of FVIII should be monitored [87,99]. Furthermore, de novo anti-rpFVIII inhibitors can be developed in these patients, leading to discontinuation of the treatment [100,101].…”
Section: Management Of Acute Bleeding Eventsmentioning
confidence: 99%
See 1 more Smart Citation
“…When rpFVIII is chosen as the initial treatment, a dose of 200 U/kg, followed by additional doses to sustain the levels of FVIII > 50% through the treatment, is used [87]. Studies are suggesting that, during therapy with rpFVIII, the activity of FVIII should be monitored [87,99]. Furthermore, de novo anti-rpFVIII inhibitors can be developed in these patients, leading to discontinuation of the treatment [100,101].…”
Section: Management Of Acute Bleeding Eventsmentioning
confidence: 99%
“…Plasma-deprived FVIIa/FX has been also evaluated in patients with AHA, with favorable outcomes without an increase in the thrombotic risk [ 94 ]. Emicizumab, a monoclonal antibody restoring the function of missing FVIII by connecting FIXa and FX, has been used off-label in AHA [ 95 , 96 , 97 , 98 , 99 ]. Figure 2 presents the initial clinical administration of the patient with AHA in the emergency room department.…”
Section: Treatment Approaches In Ahamentioning
confidence: 99%